{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T10:26:32Z","timestamp":1742379992927,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nTherapy results in pediatric Hodgkin lymphoma reflect remarkable progress in pediatric oncology. In the last decade, relevant development of new therapeutic options for children with refractory or relapsed disease has been made. In this study, we retrospectively analyzed therapy results and risk factors in children treated in a single oncology center according to five therapeutic protocols. Data from 114 children treated by a single institution between 1997 and 2022 were analyzed. Classic Hodgkin lymphoma therapy results were divided into four therapeutic periods: 1997\u20132009, 2009\u20132014, 2014\u20132019, and 2019\u20132022. For nodular lymphocyte-predominant Hodgkin lymphoma, data from one therapeutic protocol was analyzed. For the entire group, the 5-year probability of overall survival was 93.5%. There were no statistically significant differences between therapeutic periods. The occurrence of B symptoms at diagnosis and incidence of relapse were risk factors for death (<jats:italic>p<\/jats:italic>\u2009=\u20090.018 and <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Relapse occurred in 5 cases. The 5-year probability of relapse-free survival for the entire group was 95.2%, without significant differences between groups. Patients treated between 1997 and 2009 had over a sixfold higher risk for events, defined as primary progression, relapse, death, or incidence of secondary malignancies (OR\u2009=\u20096.25, <jats:italic>p<\/jats:italic>\u2009=\u20090.086). The 5-year probability of event-free survival for all patients was 91.3%. Five patients died, and the most common cause of death was relapse. Modern therapeutic protocols in pediatric Hodgkin lymphoma are marked by excellent outcomes. Patients with disease relapses have a notably high risk of death, and the development of new therapeutic options for this group remains one of the main goals of current trials.<\/jats:p>","DOI":"10.1007\/s00277-023-05268-5","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T09:03:38Z","timestamp":1684314218000},"page":"2109-2117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapy results in pediatric Hodgkin lymphoma \u2014 does less mean better? Experience from a single children\u2019s oncology center"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7419-1936","authenticated-orcid":false,"given":"Joanna","family":"Stankiewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Ko\u0142tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Demidowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Bartoszewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylwia","family":"Ko\u0142tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Czy\u017cewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Richert-Przygo\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"D\u0119bski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Pogorza\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Tejza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Cisek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Ksi\u0119\u017cniakiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Jatczak-Gaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Marja\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlena","family":"Salamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"D\u0105browska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Urba\u0144czyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Grze\u015bk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"Jaremek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"\u0141\u0119cka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliwia","family":"Grochowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Styczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"issue":"3","key":"5268_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.achaem.2013.07.004","volume":"44","author":"W Balwierz","year":"2013","unstructured":"Balwierz W, Dzikowska K, Szurgot M, Klekawka T, Moryl-Bujakowska A (2013) Post\u0119py w leczeniu ch\u0142oniaka Hodgkina u dzieci i m\u0142odzie\u017cy. Acta Haematol Polonica 44(3):182\u2013187. https:\/\/doi.org\/10.1016\/j.achaem.2013.07.004","journal-title":"Acta Haematol Polonica"},{"key":"5268_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3322\/caac.21438","volume":"68","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag S, Ambinder RF (2018) Hodgkin lymphoma: a review and update on recent progress. CA: Cancer J Clinic 68:116\u201332. https:\/\/doi.org\/10.3322\/caac.21438","journal-title":"CA: Cancer J Clinic"},{"key":"5268_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1182\/blood.2020009178","volume":"138","author":"RH Advani","year":"2021","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA et al (2021) Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 138:427\u2013438. https:\/\/doi.org\/10.1182\/blood.2020009178","journal-title":"Blood"},{"key":"5268_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood-2018-99-111279","volume":"132","author":"P Harker-Murray","year":"2018","unstructured":"Harker-Murray P, Leblanc T, Mascarin M, Mauz-K\u00f6rholz C, Michel G, Cooper S et al (2018) Response-adapted therapy with nivolumab and brentuximab vedotin (BV), followed by BV and bendamustine for suboptimal response, in children, adolescents, and young adults with standard-risk relapsed\/refractory classical Hodgkin lymphoma. Blood 132:927. https:\/\/doi.org\/10.1182\/blood-2018-99-111279","journal-title":"Blood"},{"key":"5268_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/00043426-200606000-00008","volume":"28","author":"FH Kung","year":"2006","unstructured":"Kung FH, Schwartz CL, Ferree CR, London WB, Ternberg JL, Behm FG et al (2006) POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children\u2019s Oncology Group. J Pediatr Hematol Oncol 28:362\u2013368. https:\/\/doi.org\/10.1097\/00043426-200606000-00008","journal-title":"J Pediatr Hematol Oncol"},{"key":"5268_CR6","doi-asserted-by":"publisher","first-page":"e28562","DOI":"10.1002\/pbc.28562","volume":"68","author":"AC Lo","year":"2021","unstructured":"Lo AC, Dieckmann K, Pelz T, Gallop-Evans E, Engenhart-Cabillic R, Vordermark D et al (2021) Pediatric classical Hodgkin lymphoma. Pediatr Blood Cancer 68:e28562. https:\/\/doi.org\/10.1002\/pbc.28562","journal-title":"Pediatr Blood Cancer"},{"key":"5268_CR7","first-page":"375","volume":"67","author":"W Balwierz","year":"2010","unstructured":"Balwierz W, Klekawka T, Moryl-Bujakowska A, Matysiak M, Sopy\u0142o B, Wachowiak J et al (2010) Czy dzieci z chorob\u0105 Hodgkina mog\u0105 by\u0107 leczone wy\u0142\u0105cznie chemioterapi\u0105? Przegl\u0105d Lekarski 67:375\u2013381","journal-title":"Przegl\u0105d Lekarski"},{"key":"5268_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","volume":"23","author":"C Mauz-K\u00f6rholz","year":"2022","unstructured":"Mauz-K\u00f6rholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A et al (2022) Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol 23:125\u2013137. https:\/\/doi.org\/10.1016\/S1470-2045(21)00470-8","journal-title":"Lancet Oncol"},{"key":"5268_CR9","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","volume":"7","author":"T Lister","year":"1989","unstructured":"Lister T, Crowther D, Sutcliffe S, Glatstein E, Canellos G, Young R et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting. J Clin Oncol 7:1630\u20131636. https:\/\/doi.org\/10.1200\/JCO.1989.7.11.1630","journal-title":"J Clin Oncol"},{"key":"5268_CR10","doi-asserted-by":"publisher","first-page":"6223","DOI":"10.3390\/jcm11206223","volume":"11","author":"E Lopci","year":"2022","unstructured":"Lopci E, Elia C, Catalfamo B, Burnelli R, De Re V, Mussolin L et al (2022) Prospective evaluation of different methods for volumetric analysis on [18F] FDG PET\/CT in pediatric Hodgkin lymphoma. J Clin Med 11:6223. https:\/\/doi.org\/10.3390\/jcm11206223","journal-title":"J Clin Med"},{"key":"5268_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/bjh.16197","volume":"187","author":"SM Castellino","year":"2019","unstructured":"Castellino SM, Parsons SK, Kelly KM (2019) Closing the survivorship gap in children and adolescents with Hodgkin lymphoma. Br J Haematol 187:573\u2013587. https:\/\/doi.org\/10.1111\/bjh.16197","journal-title":"Br J Haematol"},{"key":"5268_CR12","first-page":"25","volume":"63","author":"W Balwierz","year":"2006","unstructured":"Balwierz W, Moryl-Bujakowska A, Kaczmarek-Kanold M, Wachowiak J, Matysiak M, Sopy\u0142o B et al (2006) Ocena stanu zdrowia os\u00f3b z zako\u0144czonym w dzieci\u0144stwie leczeniem choroby Hodgkina: raport Polskiej Pediatrycznej Grupy ds. Leczenia Bia\u0142aczek i Ch\u0142oniak\u00f3w. Przegl\u0105d Lekarski 63:25\u201328","journal-title":"Przegl\u0105d Lekarski"},{"key":"5268_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1055\/s-2003-39372","volume":"215","author":"W D\u00f6rffel","year":"2003","unstructured":"D\u00f6rffel W, L\u00fcders H, R\u00fchl U, Albrecht M, Marciniak H, Parwaresch R et al (2003) Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin\u2019s disease in children and adolescents: analysis and outlook. Klin Padiatr 215:139\u2013145. https:\/\/doi.org\/10.1055\/s-2003-39372","journal-title":"Klin Padiatr"},{"key":"5268_CR14","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","volume":"28","author":"C Mauz-K\u00f6rholz","year":"2010","unstructured":"Mauz-K\u00f6rholz C, Hasenclever D, D\u00f6rffel W, Ruschke K, Pelz T, Voigt A et al (2010) Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin\u2019s lymphoma: the GPOH-HD-2002 study. J Clin Oncol 28:3680\u20133686. https:\/\/doi.org\/10.1200\/JCO.2009.26.9381","journal-title":"J Clin Oncol"},{"key":"5268_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1053\/j.semnuclmed.2017.01.001","volume":"47","author":"R Kluge","year":"2017","unstructured":"Kluge R, Kurch L, Georgi T, Metzger M (2017) Current role of FDG-PET in pediatric Hodgkin\u2019s lymphoma. Semin Nucl Med 47:242\u2013257. https:\/\/doi.org\/10.1053\/j.semnuclmed.2017.01.001. (Elsevier)","journal-title":"Semin Nucl Med"},{"key":"5268_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2967\/jnumed.116.176511","volume":"58","author":"S Bakhshi","year":"2017","unstructured":"Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S et al (2017) Posttreatment PET\/CT rather than interim PET\/CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma: a prospective study comparing PET\/CT with conventional imaging. J Nucl Med 58:577\u2013583. https:\/\/doi.org\/10.2967\/jnumed.116.176511","journal-title":"J Nucl Med"},{"key":"5268_CR17","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1097\/MPH.0000000000001879","volume":"43","author":"T Chotsampancharoen","year":"2021","unstructured":"Chotsampancharoen T, Chavananon S, Sripornsawan P, Duangchu S, McNeil E (2021) Outcome and prognostic factors of childhood Hodgkin disease: experience from a single tertiary center in Thailand. J Pediatr Hematol Oncol 43:e85\u2013e89. https:\/\/doi.org\/10.1097\/MPH.0000000000001879","journal-title":"J Pediatr Hematol Oncol"},{"key":"5268_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/pbc.24851","volume":"61","author":"PD Harker-Murray","year":"2014","unstructured":"Harker-Murray PD, Drachtman RA, Hodgson DC, Chauvenet AR, Kelly KM, Cole PD (2014) Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. Pediatr Blood & Cancer 61:579\u2013586. https:\/\/doi.org\/10.1002\/pbc.24851","journal-title":"Pediatr Blood & Cancer"},{"key":"5268_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/HS9.0000000000000329","volume":"4","author":"S Daw","year":"2020","unstructured":"Daw S, Hasenclever D, Mascarin M, Fern\u00e1ndez-Teijeiro A, Balwierz W, Beishuizen A et al (2020) Risk and response adapted treatment guidelines for managing first relapsed and refractory classical Hodgkin lymphoma in children and young people. recommendations from the euronet pediatric Hodgkin lymphoma group. HemaSphere 4:1. https:\/\/doi.org\/10.1097\/HS9.0000000000000329","journal-title":"HemaSphere"},{"key":"5268_CR20","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.1200\/JCO.2005.07.930","volume":"23","author":"S Gn","year":"2005","unstructured":"Gn S, D\u00f6rffel W, Claviez A, K\u00f6rholz D, Mann G, Scheel-Walter H-G et al (2005) Salvage therapy of progressive and recurrent Hodgkin\u2019s disease: results from a multicenter study of the pediatric DAL\/GPOH-HD study group. J Clin Oncol 23:6181\u20136189. https:\/\/doi.org\/10.1200\/JCO.2005.07.930","journal-title":"J Clin Oncol"},{"key":"5268_CR21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/00043426-200411000-00010","volume":"26","author":"S Stoneham","year":"2004","unstructured":"Stoneham S, Ashley S, Pinkerton CR, Wallace WH, Shankar AG, Group UKCsCS (2004) Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol 26:740\u20135. https:\/\/doi.org\/10.1097\/00043426-200411000-00010","journal-title":"J Pediatr Hematol Oncol"},{"key":"5268_CR22","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.1182\/bloodadvances.2021005268","volume":"5","author":"CJ Forlenza","year":"2021","unstructured":"Forlenza CJ, Gulati N, Mauguen A, Absalon MJ, Castellino SM, Franklin A et al (2021) Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed\/refractory Hodgkin lymphoma. Blood Adv 5:5519\u20135524. https:\/\/doi.org\/10.1182\/bloodadvances.2021005268","journal-title":"Blood Adv"},{"key":"5268_CR23","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","volume":"131","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA et al (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood J Am Soc Hematol 131:1183\u20131194. https:\/\/doi.org\/10.1182\/blood-2017-10-811224","journal-title":"Blood J Am Soc Hematol"},{"key":"5268_CR24","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1200\/JCO.2014.59.4853","volume":"33","author":"C Mauz-K\u00f6rholz","year":"2015","unstructured":"Mauz-K\u00f6rholz C, Metzger ML, Kelly KM, Schwartz CL, Castellanos ME, Dieckmann K et al (2015) Pediatric hodgkin lymphoma. J Clin Oncol 33:2975\u20132985. https:\/\/doi.org\/10.1200\/JCO.2014.59.4853","journal-title":"J Clin Oncol"},{"key":"5268_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/08880018.2021.1894278","volume":"38","author":"T Klekawka","year":"2021","unstructured":"Klekawka T, Balwierz W, Brozyna A, Chaber R, Dadela-Urbanek A, Koltan A et al (2021) Nodular lymphocyte predominant Hodgkin lymphoma: experience of Polish Pediatric Leukemia\/Lymphoma Study Group. Pediatr Hematol Oncol 38:609\u2013619. https:\/\/doi.org\/10.1080\/08880018.2021.1894278","journal-title":"Pediatr Hematol Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05268-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05268-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05268-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:06:11Z","timestamp":1689231971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05268-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5268"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05268-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"7 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}